Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 06, 2023 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer

SEATTLE, July 06, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
June 28, 2023 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

SEATTLE and SAN FRANCISCO, June 28, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of...
June 27, 2023 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces $10M Stock Repurchase Program

SEATTLE, June 27, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
June 22, 2023 16:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023

SEATTLE, June 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
June 21, 2023 10:13 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

SEATTLE, June 21, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
June 14, 2023 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC

SEATTLE, June 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
June 12, 2023 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
June 01, 2023 09:10 ET | Source: Atossa Therapeutics, Inc.

Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer

SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
May 15, 2023 09:10 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

Two Phase 2 trials investigating (Z)-endoxifen in neoadjuvant setting initiated and are enrolling patientsFull enrollment of Phase 2 KARISMA mammographic breast density study expected by end of...
May 09, 2023 09:15 ET | Source: Atossa Therapeutics, Inc.

Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right